Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCRαβ/CD19 Depleted HSCT and Kidney Transplant
NCT05508009Phase 2Recruiting
- Start
- Jan 2023
- Primary completion
- Oct 2032
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of T-cell receptor alpha/beta and CD19 depleted hematopoietic stem cells in chronic kidney disease (CKD), kidney failure, Schimke immuno-osseous dysplasia (SIOD) and 3 more (4 cohorts). Primary endpoint: Number of patients who are able to discontinue immunosuppression post-KT. Started Jan 2023; status: recruiting.
02
Drugs
T-cell receptor alpha/beta and CD19 depleted hematopoietic stem cells
03
Conditions
chronic kidney disease (CKD)kidney failureSchimke immuno-osseous dysplasia (SIOD)focal segmental glomerulosclerosis (FSGS)cystinosis
Beyond the preview
Go deeper on NCT05508009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508009.